Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

VistaGen Therapeutics Inc. - news published 248 - readings 3.149

BACK

VistaGen Therapeutics Inc.

Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 10, 2025, Vistagen Therapeutics, Inc. (the " Company ") received notice from Cynthia L. Anderson, the Company's Chief Financial Officer and principal financial and accounting officer, of her decision ...

15.09.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

11.09.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

11.09.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

11.09.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

11.09.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

11.09.2025

VistaGen Therapeutics Inc.

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 9, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a f ...

09.09.2025

VistaGen Therapeutics Inc.

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care SOUTH SAN FRAN ...

07.08.2025

VistaGen Therapeutics Inc.

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update (Form 8-K)

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline target ...

07.08.2025

VistaGen Therapeutics Inc.

Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)

Item 2. MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Note Regarding Forward-Looking Statements Certain statements in this Quarterly Report on Form 10-Q (Quarterly Report or Report) may constitute "forward-looking statements" for purposes of the federal securities laws, including the safe harbor provisions of Secti ...

07.08.2025

VistaGen Therapeutics Inc.

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 31, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 ...

31.07.2025

VistaGen Therapeutics Inc.

Proxy Statement (Form DEF 14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2)) ?? ...

28.07.2025

VistaGen Therapeutics Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

28.07.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

01.07.2025

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

01.07.2025

VistaGen Therapeutics Inc. - news published 248 - readings 3.149

VistaGen Therapeutics Inc.

Proxy Results, Management Change/Compensation (Form 8-K)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

VistaGen Therapeutics Inc.

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

VistaGen Therapeutics Inc.

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

VistaGen Therapeutics Inc.

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update (Form 8-K)

VistaGen Therapeutics Inc.

Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)

VistaGen Therapeutics Inc.

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

VistaGen Therapeutics Inc.

Proxy Statement (Form DEF 14A)

VistaGen Therapeutics Inc.

Additional Proxy Soliciting Materials (Form DEFA14A)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

VistaGen Therapeutics Inc.

Statement of Changes in Beneficial Ownership (Form 4)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member